Clinical Trials Browser

Completed × Recurrence × zanubrutinib × Clear all

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03145064 2024-10-26

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Phase 2 Completed

41 enrolled 15 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03206918 2024-10-26

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

91 enrolled 14 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence